On Tuesday, Denali Therapeutics Inc (NASDAQ: DNLI) opened lower -4.17% from the last session, before settling in for the closing price of $14.62. Price fluctuations for DNLI have ranged from $10.57 to $33.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -18.33% at the time writing. With a float of $125.73 million, this company’s outstanding shares have now reached $145.25 million.
The firm has a total of 422 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Denali Therapeutics Inc is 13.46%, while institutional ownership is 92.15%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -18.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.56% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Check out the current performance indicators for Denali Therapeutics Inc (DNLI). In the past quarter, the stock posted a quick ratio of 9.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.74 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Analysing the last 5-days average volume posted by the [Denali Therapeutics Inc, DNLI], we can find that recorded value of 1.48 million was better than the volume posted last year of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 33.54%. Additionally, its Average True Range was 0.82.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 24.97%, which indicates a significant decrease from 40.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.14% in the past 14 days, which was lower than the 70.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.18, while its 200-day Moving Average is $20.83. Now, the first resistance to watch is $14.61. This is followed by the second major resistance level at $15.20. The third major resistance level sits at $15.53. If the price goes on to break the first support level at $13.69, it is likely to go to the next support level at $13.36. Should the price break the second support level, the third support level stands at $12.77.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are currently 145,276K shares outstanding in the company with a market cap of 2.04 billion. Presently, the company’s annual sales total 0 K according to its annual income of -422,770 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -132,970 K.
